Novo Nordisk Won't Be Pursuing Victoza for Type 1 Diabetes
Novo petitions FDA to require Victoza copies to go through clinical trials, pointing to complex manufacturing | Fierce Pharma
Victoza Novo Nordisk A/S injektionsvæske, opløsning i fyldt pen 6 mg/ml
Novo Nordisk warns of lower profits and sales for 2017
Paula Deen's Pharma Deal Suspended by Novo Nordisk - Eater
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Rx Item-Victoza Pen 0.6Mg 0.1 Inj 3 By Novo Nordisk Pharm
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QKOPLCUOOVIV5EFKGE7WWNSN3U.jpg "U.S. experts recommend weight-loss drugs for obese children | Reuters")
U.S. experts recommend weight-loss drugs for obese children | Reuters
Novo Nordisk settles patent infringement lawsuit with Novartis — MedWatch
Novo Nordisk targets Mexico for anti-obesity drug
![Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management](http://photos.prnewswire.com/prnfull/20141224/166096 "Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management")
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
Diabetes Medicine Savings & Support | NovoCare®
Liraglutide – Next-Generation Antidiabetic Medication - Clinical Trials Arena
Novo Nordisk Liraglutide VICTOZA, Non prescription, Treatment: Insulin at Rs 3350/pice in New Delhi
Pharmaceutical Stocks Eye A Big New Market For Their Diabetes Drugs: Obesity | Investor's Business Daily
Novo's Victoza has been approved in the EU - Nordic Life Science – the leading Nordic life science news service
